Compare CEVA & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CEVA | ETON |
|---|---|---|
| Founded | 1999 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 573.9M | 510.1M |
| IPO Year | 2002 | 2018 |
| Metric | CEVA | ETON |
|---|---|---|
| Price | $19.10 | $25.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | $30.33 | ★ $39.33 |
| AVG Volume (30 Days) | 282.1K | ★ 436.0K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $87,507,000.00 | $79,950,000.00 |
| Revenue This Year | $12.37 | $40.90 |
| Revenue Next Year | $13.82 | $47.23 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 20.45 | ★ 104.94 |
| 52 Week Low | $17.02 | $11.38 |
| 52 Week High | $30.88 | $25.99 |
| Indicator | CEVA | ETON |
|---|---|---|
| Relative Strength Index (RSI) | 48.17 | 72.66 |
| Support Level | $17.92 | $16.79 |
| Resistance Level | $19.80 | N/A |
| Average True Range (ATR) | 0.89 | 1.43 |
| MACD | 0.19 | 0.20 |
| Stochastic Oscillator | 73.01 | 86.19 |
CEVA Inc is a licensor of signal-processing intellectual property. Through partnerships with semiconductor companies and original equipment manufacturers globally, the company helps produce devices for a range of end markets. OEMs and semiconductor companies choose to sell products with CEVA equipment to wireless, consumer, automotive, and Internet of Things companies. Revenue is derived primarily from licensing fees and related revenue, and royalties generated from the shipments of products utilizing its intellectual properties. CEVA also engages in the training and sale of development systems.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.